5 unknown, 1 active not recruiting, 1 recruiting, 1 terminated. 7 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 5, Active not recruiting 1, Terminated 1 |
| Phase 1 | 4 | Unknown 3, Recruiting 1 |
Follow EBV-Positive DLBCL, Nos: new trials by email Literature Review of EBV-Positive DLBCL, Nos trials Research Report on EBV-Positive DLBCL, Nos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Patrick C. Johnson, MD | 28 | 2023-03-01 | 2026-01-29 |
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas Nanatinostat in combination with valganciclovir - Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS | Phase 2 | Terminated | Viracta Therapeutics, Inc. | 102 | 2021-05-28 | 2025-07-28 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL Zanubrutinib, Tislelizumab - Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos | Phase 2 | Unknown | Ruijin Hospital | 40 | 2021-01-01 | 2021-03-30 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS Sintilimab, Rituximab, Cyclophosphamide - EBV-Positive DLBCL, Nos | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 55 | 2019-01-01 | 2019-11-29 |
Pyloric Stenosis, Hypertrophic (8) · Lymphoma, Large B-Cell, Diffuse (3) · Recurrence (2) · Burkitt Lymphoma (1) · Epstein-Barr Virus Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, Primary Effusion (1) · Plasmablastic Lymphoma (1) · Waldenstrom Macroglobulinemia (1)
Digestive System Diseases (8) · Gastric Outlet Obstruction (8) · Gastrointestinal Diseases (8) · Pyloric Stenosis (8) · Stomach Diseases (8) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Disease Attributes (3) · Lymphoma, B-Cell (3)
Cyclophosphamide (2) · Rituximab (2) · tislelizumab (2) · Doxorubicin (1) · Lenalidomide (1) · Prednisolone (1) · R-CHOP protocol (1) · Valganciclovir (1) · Vincristine (1) · acalabrutinib (1) · apatinib (1) · camrelizumab (1) · fludarabine (1) · sintilimab (1) · spartalizumab (1)
Huiqiang Huang (3) · Patrick C. Johnson, MD (1) · Ruijin Hospital (1) · Schrödinger, Inc. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Viracta Therapeutics, Inc. (1)
China (5) · United States (3) · France (2) · Italy (2) · Spain (2) · Australia (1) · Brazil (1) · Canada (1) · Germany (1) · Israel (1) · Malaysia (1) · Moldova (1) · Poland (1) · Romania (1) · Singapore (1)
Connor Johnson, MD (1) · Darrel P Cohen, MD, PhD (1) · Frank G Basile, M.D. (1) · Huiqiang Huang, Professor (1) · Wei Xu, M.D., Ph.D. (1) · Weili Zhao, PhD, MD (1)